Poly Chrome

Polychrome Therapeutics is a synthetic biology company pioneering the development of large-scale synthetic DNA and artificial chromosomes for therapeutic applications. Spun out from NYU Langone Health and led by synthetic genomics pioneer Jef Boeke, the company's "Polychrome" platform enables the precise engineering of complex genetic circuits and multi-gene pathways. This technology aims to address the payload limitations of traditional viral vectors, allowing for more sophisticated cell and gene therapies that require the delivery of multiple genes. The company is currently focused on advancing its platform to create next-generation treatments for oncology and rare genetic disorders. By "writing" DNA at an unprecedented scale, Polychrome seeks to enable the next frontier of genomic medicine.